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Abstract: Canine leishmaniosis has a wide range of disease severity from mild (stage I), to severe
(stages II–III), or very severe disease (stage IV). The objective of the study was to evaluate and
compare serum antibody levels, Leishmania infantum specific IFN-γ production and TLR2 and TLR4
transcripts in non-stimulated blood from dogs with different clinical stages at the time of diagnosis
as well as blood parasitemia. Enzyme-Linked ImmunoSorbent Assay (ELISAs) were performed to
determine serum antibody levels and IFN-γ production and quantitative polymerase chain reaction
(qPCRs) in order to determine blood parasite load and TLR2 and TLR4 transcripts. Older dogs were
significantly affected by more severe disease with higher antibody levels and blood parasitemia
than dogs with mild disease. IFN-γ production was significantly higher in dogs with stage I disease
when compared to dogs with more severe disease. Relative quantification of TLR2 in dogs with mild
disease was similar to that of control dogs. On the other hand, TLR2 transcripts were significantly
higher in dogs with severe disease as compared with that from control healthy dogs. No differences
were found in TLR4 relative quantification between groups. This study demonstrates that dogs with
different clinical stages of leishmaniosis present different levels of biological markers indicative of
different immune responses.
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1. Introduction
Canine leishmaniosis (CanL) due to Leishmania infantum is a very pleomorphic disease. Clinically,
this infection ranges from subclinical infection to very severe disease, passing through several degrees
of disease [1]. According to this clinical variability, a clinical staging system that classifies the
disease into four stages based on clinical signs, clinicopathological abnormalities, and measurement of
anti-leishmanial antibodies, was previously described [1].
Clinical and clinical-pathological findings observed in CanL are the consequence of complex
interactions between L. infantum and the genetical and immunological background of the
dog [1]. In fact, both innate and adaptive immune responses play a role in the outcome of
Leishmania infection [2,3]. However, only the adaptive immune response has been extensively
investigated in dogs. The balance between the protective T-helper (Th) 1 cellular response, which was
associated with the cytokine interferon-gamma (IFN-γ), and the humoral immune response mediated
by Th2 lymphocytes determines the clinical manifestation of the infection. A predominantly Th1
immune response is thought to provide resistance to the development of disease. On the other
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hand, a predominantly Th2 immune response correlates with antibody production and disease
progression [2,4]. Although the innate immune response has been scarcely studied in leishmaniosis,
recent data suggests that it is paramount for the ultimate outcome of Leishmania infection [2,5,6]. In this
sense, toll like receptors (TLRs), which are one of the most important pattern recognition receptor
family, are central in the early host defense against pathogen and activate adapter molecules after
binding to their ligand. The activated cascade then leads to induction or suppression of genes that
influence the inflammatory response [7].
Limited information is available regarding the role of TLRs in canine L. infantum infection.
Although, the exact role of TLRs in the pathogenesis of CanL has not been fully addressed, it would
seem that there is an association between TLR2 and its pathogenesis [2]. In fact, it has been recently
revealed that TLR2 upregulation in blood and skin seems to be associated with disease progression
in dogs [2,8], and a reduction in TLR2 transcription has been described with treatment and clinical
improvement [8]. Moreover, there is a lower expression of TLR2 in skin biopsies from dogs with
mild disease (papular dermatitis) when compared with dogs with moderate or severe disease [9].
TLRs other than TLR2 have been scarcely investigated in experimental or natural L. infantum infection
in dogs [10]. Regarding TLR4, it has been described that transcription of this TLR appears to be
similar among dogs with clinical leishmaniosis and healthy seronegative dogs at the time of diagnosis
with no changes during treatment follow-up, indicating a less important role of this TLR in clinical
leishmaniosis [8].
Cutaneous lesions are the most common clinical signs in CanL [11,12] and they are clinically
classified as typical (i.e., exfoliative dermatitis, ulcerative dermatitis of the bony prominences,
onychogryphosis, and, in an endemic area, papular dermatitis) or atypical (i.e., muco-cutaneous
nodular dermatitis, other ulcerative muco-cutaneous dermatitis than that mentioned above, sterile
pustular dermatitis, or ischaemic dermatopathy) [12]. Among the cutaneous manifestations of CanL,
papular dermatitis is considered to be a typical form in an endemic area and is indicative of stage
I leishmaniosis [13–15]. In fact, dogs with papular dermatitis commonly are young dogs without
any other clinical-pathological abnormalities and with low parasite load and granuloma formation in
skin lesions, negative or weakly positive anti-Leishmania antibody levels and specific cell-mediated
immune response studied by means of leishmanin skin test [13–15]. Furthermore, this dermatological
problem is associated with the spontaneous resolution of the lesions within 3–5 months [16]. Moreover,
normal-looking skin from dogs with stage I and papular dermatitis is less likely to present microscopic
lesions as well as harbour the parasite when compared with dogs with moderate to severe CanL [14].
Taken all of these findings together, papular dermatitis and stage I CanL is indicative of a protective
immune response associated with a good prognosis [13,16,17]. However, there are limited studies that
evaluate differences in clinical staging and adaptive and innate immune responses in CanL [18].
The hypothesis of this study is that dogs with stage I leishmaniosis and papular dermatitis
show distinctive immunological characteristics when compared with dogs with more severe disease.
Therefore, the objective of this study was to evaluate serum antibody levels, L. infantum specific IFN-γ
production, and TLR2 and TLR4 transcripts in the blood of dogs with different clinical stages of
leishmaniosis at the time of diagnosis.
2. Materials and Methods
2.1. Dogs
All of the dogs used in this study were privately owned pets, which were volunteered with client
informed consent. They remained under the care of their owners and were not housed for the purposes
of this study or held for any period of time.
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2.2. Dogs with Clinical Leishmaniosis
Forty-two dogs with typical cutaneous signs due to leishmaniosis attending different veterinarian
facilities from Catalonia (Spain): Fundació Hospital Clínic Veterinari, Universitat Autònoma de
Barcelona (UAB), Cerdanyola, Barcelona), Hospital Ars Veterinària (Barcelona), Mediterrani Veterinaris
Hospital (Reus, Tarragona), and Consultori Montsant (Falset, Tarragona), were prospectively enrolled.
In order to evaluate its clinical status, a full complete blood count (CBC), serum biochemical profile
which included creatinine, urea, total cholesterol, total protein and alanine aminotransferase (ALT),
protein serum electrophoresis, and urinalysis with urinary protein creatinine ratio (UPC) were carried
out. The hematology, biochemistry, and serum electrophoresis were performed using the following
laboratory equipment: Siemens ADVIA120 (Siemens Healthineers, Erlangen, Germany), chemistry
analyzer Olympus AU400 (Olympus Diagnostica GmbH, Hamburg, Germany) and Hydrasis system
(Sebia Hispania SA, Barcelona, Spain), respectively.
Leishmaniosis was diagnosed after visualization of amastigotes on skin cytology or biopsy with or
without Leishmania specific immunohistochemistry, as previously described [9], and/or the detection
of specific L. infantum antibody levels by quantitative serology using an in-house Enzyme-Linked
ImmunoSorbent Assay (ELISA) [19]. The classification of L. infantum antibody levels is described
in Supplementary Table S1. Dogs were classified based on LeishVet clinical stages, as previously
described [1]. In addition, blood DNA extraction and Leishmania quantitative polymerase chain
reaction (qPCR) was performed with an absolute quantification of parasites/mL of blood, a standard
curve was created. Ten-fold serial dilutions of known concentrations were made from a culture
with 107 L. infantum promastigotes/mL. Six serial dilutions were obtained to create a standard
curve. Subsequently, the value of the slope (m) and the intersection (y) of the line were calculated.
The following formula was used in order to determine the number of parasites/mL blood by PCR:
(Standard deviation − y)/m. The result was multiplied by the dilution factor of DNA (x125) to achieve
the number of parasites/mL [20]. The classification of parasite load, as described elsewhere [21], is
listed in Table S2.
2.3. Control Healthy Dogs
A total of 34 healthy dogs were enrolled. Both sexes were represented with 16 females and
18 males. Median of age was four years, with a range from six months to 10 years. Twenty-two
purebred dogs with 14 breeds were represented (golden retriever, beagle, greyhound, Labrador
retriever, border collie, schnauzer, Ibizan hound, fox hound, Ariege pointer, griffon Nivernais, Bruno
Jura hound, Dachshund, English setter), eight mixed-breed dogs were included and for four dogs
breeds were not registered. All of the dogs were seronegative and blood qPCR negative.
2.4. Whole Blood Cytokine Release Assay and Determination of Canine IFN-γ
Heparinized whole blood cytokine release assay was carried out, as previously reported [22].
Briefly, heparinized whole blood was separately mixed with three different conditions: (i) only medium
(unstimulated); (ii) medium with soluble L. infantum antigen (LSA) at a concentration of 10 µg/mL;
and, (iii) medium with the mitogen concanavalin A (ConA, 100 mg, Medicago®, Uppsala, Sweden) at
a concentration of 10 µg/mL. IFN-γ was determined in supernatants from five days after stimulation
with ConA and LSA or only medium (unstimulated), as described elsewhere [22], by a commercial
sandwich ELISA (DuoSet® ELISA by Development System R&DTM, Abingdon, UK).
Cytokine concentration from supernatants with ConA and LSA was calculated after subtracting
the IFN-γ concentration obtained from supernatants with only medium (unstimulated). Thereafter,
dogs were classified as IFN-γ producers when L infantum specific IFN-γ concentration was detectable.
Dogs were classified as IFN-γ non-producers when L. infantum specific IFN-γ concentration was at not
detectable levels [22].
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2.5. RNA Extraction, RNA Concentration and Quality and cDNA Synthesis
Half mL of Ethylenediaminetetraacetic Acid (EDTA) blood sample was transferred to a cryovial
tube that contained 1.3 mL of RNAlater (Ambion®, Thermo Fisher Scientific, Waltham, MA, USA).
Then, blood samples in cryovial tubes were left at 4 ◦C overnight and, thereafter, frozen at −80 ◦C
until used. Blood samples were thawed on ice and total RNA from 500 µL of EDTA blood was
extracted using Ribopure RNA blood kit (Ambion®, Thermo Fisher Scientific), according to the
manufacturer's instructions. A DNase digestion step was included to remove contaminating genomic
DNA using TurboDNase (Ambion®, Thermo Fisher Scientific) following manufacturer’s instructions.
RNA concentration was determined by Nanodrop device (Thermo Fisher Scientific). RNA integrity
and quality was assessed by using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA,
USA). Samples had a final concentration amongst 20–70 ng RNA/µL. All samples had an RNA Integrity
Number (RIN) value greater than 7. cDNA was generated using VILO masterscript retrotranscriptase
(Invitrogen™, Thermo Fisher Scientific), according to the manufacturer’s instructions. cDNA was
stored at −20 ◦C until used [8].
2.6. TLR2, TLR4 and Reference Housekeeping Genes qPCR
Transcription of TLR2 and TLR4 target genes (TG), as well as three reference housekeeping genes
(RG: HPRT-1, CG14980 and SDHA), was measured by qPCR using QuantStudio™ 7 Flex Real-Time
PCR System, array card, desktop (Life Technologies, Carlsbad, CA, USA) as previously described [8].
Briefly, we calculated the efficiency of target and reference amplification genes and determined optimal
efficiencies amplifications of 100% and acceptable in the range (±20%). The baseline and threshold
were established for each gene and all of the samples were processed in triplicate. The same control
sample was used as a calibrator in every plate to determine relative quantification of all the dogs
studied. Data were processed while applying the relative quantification method comparable to the
delta-delta-cycle threshold value (ddCt)-method (2ddCt) [8]. Quantitative PCR data analysed was
done by the Cloudsuite software (Life technologies™, Thermo Fisher Scientific). For normalization of
TG, expression the arithmetic mean of the three RG was taken for the calculation of a reference gene
index (RGI) [8].
2.7. Statistical Analysis
Statistical analyses were performed using the IBM SPSS Statistics Base 22.0 program for Windows
software (IBM Corporation, Armonk, NY, USA).
Standard descriptive statistics [median and range (minimum and maximum values)] were
calculated for quantitative variables. The non-parametric Mann-Whitney test was used to evaluate
differences among groups. Categorical data were expressed as percentage and statistical analysis
was performed while using the Fisher’s exact test to compare results among independent variables.
Differences were considered significant at a 5% significance level (p < 0.05).
3. Results
3.1. Dogs with Clinical Leishmaniosis
Based on clinicopathological findings and L. infantum-specific antibody levels, dogs were clinically
classified, as previously reported [1], and were distributed as follows: group A (stage I and papular
dermatitis, n = 20, Figure 1) and group B (stage II–III and ulcerative or exfoliative dermatitis, n = 22,
Figure 2).
Ten females and ten males composed group A. Median of age was 10 months (5–98). Twelve
pure bred dogs with three breeds represented and eight mixed breed dogs were included. Ten out
20 dogs were Ibizan hound dogs, one was a German pointer, and one was a Dachshund. Ten females
and 12 males constituted group B. Median of age was 52.5 months (8–153). Fifteen pure bred dogs
with 12 breeds represented (two French bull dogs, two Labrador retrievers, and one of each doberman,
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pinscher, American bull dog, schnauzer, boxer, Akita inu, greyhound, Brittany) and seven mixed breed
dogs were included. The difference of age between groups was statistically significant (Mann-Whitney
U-test, Z = 3.66999, p = 0.00024). Dogs from group A did not present laboratory abnormalities, while
dogs from group B presented typical laboratory abnormalities of clinical leishmaniosis.
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Figure 2. Crusting and scaling in the dorsal part of the muzzle (white arrow) and perinasal
depigmentation (bl ck arrow) in a schnauzer dog with stage II leishmaniosis (Group B).
3.2. Blood Leish ania qPCR
Based on Leishmania qPCR dogs from group A were classified as negative (n = 12), low positive
(n = 3), or medium positive (n = 1). The parasite load evaluation was not possible in four dogs from this
group due to lack of sample. On the other hand, dogs from group B were classified as negative (n = 7),
low (n = 9), medium (n = 4) and high positive (n = 2). A higher percentage of positive Leishmania qPCR
in blood were found in group B when compared with group A (Fisher´s exact test, p = 0.0201).
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Group A dogs had lower parasite load (median and range (R): 0 parasite/mL (0–33.49)) than
those from group B (median and R: 2.54 (0–475.07); Mann-Whitney U-test, Z = −2.664, p = 0.012).
3.3. Leishmania infantum Specific Antibody Levels
Dogs from group A were serologically classified as follows: negative (n = 11), very low positive
(n = 3), low positive (n = 4), and medium positive (n = 2). On the other hand, dogs from group B were
classified as very low positive (n = 1), low positive (n = 4), medium positive (n = 12), high positive
(n = 3), and very high positive (n = 2). A higher percentage of seroreactive dogs was found in group B
when compared with group A (Fisher´s exact test, p = 0.0001).
Group A dogs had lower levels of antibodies (median and R: 25 (5.7–529.5) EU) than those from
group B (median and R: 1609 (86.8–90730.2) EU); Mann-Whitney U-test, Z = 3.53323, p = 0.00042).
3.4. Leishmania infantum Specific IFN-γ Production after Blood Stimulation
Cytokine analysis was performed in 19 out of 20 dogs from group A and in 15 out of 22 dogs
from group B due to lack of samples. Fifteen of 19 dogs (79%) from group A and six out 15 (40%) from
group B were classified as IFN-γ producers (Fisher exact test, p = 0.0337).
The median and R of IFN-γ production from groups A and B were 710 (0–20300) pg/mL and 0
(0–2413) pg/mL, respectively. There was a higher IFN-γ production in group A dogs when compared
to those of group B (Mann-Whitney U-test, Z = 2.45047, p = 0.0143).
3.5. TLRs Transcripts
TLRS transcripts are presented in Figure 3. Relative quantification of TLR2 in group A (median
and R: 1.2 (0.6–4.2) folds) was similar than that of control dogs (median and R: 1.2 (0.1–3.2) folds,
Mann-Whitney U-test, Z = −0.24897, p = 0.8). On the other hand, relative quantification of TLR2 in
group B (median and R: 1.9 (0.9–12.4)) was significantly higher when compared with that from control
healthy dogs (Mann-Whitney U-test, Z = −2.41119, p = 0.016). Although no statistically significant,
the expression of TLR2 in the group A was lower than that of the group B (Mann-Whitney U-test,
Z = 1.6225, p = 0.1).
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The expression of TLR4 mRNA in control dogs was of a median and R of 2.6 (0.5–13) folds and
was similar to that of dogs from group A (median and R: 4.4 (0.7–19.8) folds; Mann-Whitney U-test,
Z = −0.92475, p = 0.36) and to that from group B (median: 3.7 (1.1–32.8) folds); Mann-Whitney U-test,
Z = −1.88358, p = 0.06). Although not statistically significant, TLR4 mRNA expression in dogs with
leishmaniosis was higher than that of control group.
4. Discussion
The results of the present study support our hypothesis that dogs with stage I leishmaniosis and
papular dermatitis show distinctive immunological characteristics when compared with dogs with
more severe disease at the time of diagnosis.
Dogs with stage I and papular dermatitis reported herein were more frequently serologically
negative than the dogs with stage II–III. Moreover, in agreement with a previous study [14],
we demonstrated that dogs with stage I and papular dermatitis had significantly lower levels of
Leishmania antibodies than dogs with more severe disease. Clinical CanL is often associated with a
humoral response (Th2 driven), which is non-protective and denotes failure to control the infection.
Serologically negative and/or low positive dogs studied herein were further diagnosed by means of
skin cytology, histopathology, and/or PCR. It is well established that dogs with mild clinical signs,
such as solitary lymphadenomegaly or papular dermatitis, may present with negative to low positive
antibody levels [23], as described in the present study. Therefore, lack or low humoral immune
response elicited in dogs with stage I and papular dermatitis, may be indicative of a polarized specific
cellular immune response (Th1 driven), which might confer protection against disease progression.
In the present study, dogs with stage I and papular dermatitis were more commonly IFN-γ
producers than dogs with more severe disease. In addition, Leishmania-specific IFN-γ concentrations
were superior in dogs with papular dermatitis than in dogs with clinically more severe cutaneous
forms. However, it is noteworthy that four dogs with mild disease were IFN-γ non–producers and
that six dogs with more severe disease were IFN-γ producers. The results of the present study are in
agreement with previous studies, which have shown that IFN-γ non-producers are usually classified
in a more severe clinical staging than IFN-γ producers [18], and that IFN-γ concentration increase
with long-term anti-Leishmania treatment, together with clinical improvement in dogs that do not
produce IFN-γ at diagnosis [22]. Although, limited information regarding L. infantum specific IFN-γ
production in stimulated blood in sick dogs is available, it seems that this assay is a reliable method
of measurement of T cell-mediated immunity in CanL [24] and human leishmaniosis [25]. It is well
established that Th1 lymphocytes mainly drive IFN-γ production in stimulated blood. However,
natural killer (NK) cells, which play important roles in innate immune responses, may secrete this
cytokine in response to IL-12. NK cells constitute 5% to 15% of the mononuclear cells in the blood.
Therefore, the proportion of IFN-γ detected in blood from this origin is likely to be low. Identification
of circulating cellular subsets expressing this immune marker was not carried out in the present study;
therefore IFN-γ production cannot be conclusively attributed to an adaptive immune response [26].
A presumed T cellular immune response in dogs with stage I and papular dermatitis, is, therefore,
thought to provide resistance to the progression of disease in those patients. In fact, previous published
data have demonstrated a good clinical outcome with spontaneous resolution and an apparent lack of
disease progression in dogs affected of papular dermatitis and stage I [16,17]. Moreover, a recent study
have revealed a lack of disease progression in a cohort of untreated dogs with papular dermatitis and
stage I leishmaniosis, followed during one year after the diagnosis [15]. However, it is interesting to
highlight that those four IFN-γ non-producer dogs with papular dermatitis and stage I leishmaniosis
would deserve a close and strict follow-up.
Another limitation of this study is that cytokine immune profile related to Th2 immune response
(i.e., TGF-β, IL10 or IL-4) was not evaluated in these dogs. Analysis of these cytokines in stimulated
blood from dogs with leishmaniosis has been scarcely described, although an association was found
between parasite specific IL-10 production and disease progression [27]. Using the same method that
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as employed in the present study, L. infantum specific IL-10 production after blood stimulation did
not seem to be a disease severity marker since it was not detected in 64% of the patients and in those
that was detected there was no correlation with the severity of the disease [22]. Therefore, although
polarized Th1 immune response is strongly suggested in dogs with stage I and papular dermatitis, a
Th2 like cytokine immune profile has not been ruled out in the present study.
There are limited data available on expression of TLRs in CanL. Therefore, the role of TLRs in the
pathogenesis of this disease has not been fully addressed [10,28–31]. This study demonstrates that dogs
with stage I and papular dermatitis presented a TLR2 transcription in the non-stimulated blood that
was similar to healthy control dogs. On the other hand, there was a significantly higher up regulation
of TLR2 in non-stimulated blood from dogs with severe clinical leishmaniosis at the time of diagnosis
when compared with healthy control dogs. Although not being statistically significant, TLR2 transcripts
were lower in stage I and papular dermatitis than in dogs with clinically more severe CanL. Although
the cell source of increase in the expression of TLR2 was not determined in the present study, it is likely
that the main source of the upregulation of TLR2 was firstly neutrophils and secondly monocytes
and NK cells. Neutrophils are the predominant white cells in whole blood in canines. In addition, it
has been also demonstrated that TLR2 protein is easily detectable by flow cytometry on the canine
peripheral blood granulocyte and monocyte cell surface, and is rarely present on lymphocytes [32].
This is similar to what is found in humans where lymphocytes do not express TLR2 in unstimulated
blood [33]. Dogs with moderate clinical leishmaniosis have a high parasite load in several tissues,
including the bone marrow [34,35], and this might be the reason for a major up regulation of TLR2 in
unstimulated blood, as Leishmania lipophosphoglycans are recognized by TLR2 [36] and it is likely that
other parasite ligands are also involved in TLR2 recognition of Leishmania [37]. In addition, myeloid
hyperplasia is a common finding in bone marrow of sick dogs with leishmaniosis [38]. Neutrophils
and monocytes are released from the bone marrow to the peripheral blood, and thereafter they migrate
to tissues where they die. Neutrophils or monocytes do not recirculate in peripheral blood. So,
we hypothesize that it is likely that an upregulation of TLR2 happens in the bone marrow of dogs
with more severe disease due to high parasite loads [34,35]. This high expression of TLR2 remains
in neutrophils when they circulate in the peripheral blood, while it does not occur in dogs with
mild disease.
Our results in unstimulated blood are in agreement with a previous study that described higher
expression of TLR2 by immunohistochemistry in skin biopsies from cutaneous lesions in dogs with at
least moderate disease (LeishVet stage II) when compared with dogs with mild disease due to papular
dermatitis [9]. When considering these facts, it would seem that the transcription of TLR2 is not
compartmentalized between the dermal tissue and the blood in diseased dogs. TLR2 appears to be a
marker of inflammation in dogs, as demonstrated in the present study and in other canine inflammatory
diseases, such as inflammatory bowel disease, immunomediated or bacterial arthritis, canine sino-nasal
aspergillosis, and lymphoplasmacytic rhinitis or pyometra [39–42]. Based on published information,
TLR2 up regulation appears to be associated with moderate to severe disease, suggesting an active
innate immune and proinflammatory responses due to the presence of a high Leishmania parasite
load or cellular damage (endogenous damage-associated molecular patterns (DAMPs), also called
alarmins) [43], as mentioned above. In a study from Brazil, a high parasite load was found along with
increased frequency and expression of TLR2 in cells from the colon of sick dogs [29]. In addition, the up
regulation of TLR-2 genes has been positively associated with parasite load in the skin of naturally
infected dogs [44]. According to this, parasite load in papular dermatitis has been demonstrated to
be lower than in more severe cutaneous CanL states [14]. Moreover, dogs with papular dermatitis
and stage I leishmaniosis show less microscopic skin lesions and parasite load in clinically healthy
skin than dogs with more severe disease [14]. Therefore, a lower up regulation of TLR2 in this profile
of dogs may be associated with this lower Leishmania parasite load. In addition, dogs with papular
dermatitis and stage I leishmaniosis described in this study presented a significantly lower blood
parasitemia when compared with dogs with at least moderate disease.
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The present results showed that TLR4 transcript in non-stimulated blood is unchanged among
the groups studied. This finding is in agreement with previous studies performed on CanL [8], in
which TLR4 transcription was unchanged when compared with healthy dogs, and might indicate a
mechanism of parasite immune system evasion or a less important role of this TLR in clinical CanL.
This is in agreement with studies that were performed in cutaneous lesions due to Leishmania braziliensis
in humans, which demonstrated that TLR2 is the most common TLR expressed during active disease
mainly by macrophages while TLR4 is scarcely expressed [45].
Although TLRs represent an important component of the innate immunity, there are many other
inflammatory factors involved in this initial immune response, such as immunity cells, cell-associated
molecules other than TLRs, and soluble molecules. Therefore, further studies regarding the analysis of
these other factors is necessary in order to elucidate how innate immune responses prime the adaptive
immune responses in L. infantum infection in dogs.
5. Conclusions
In conclusion, this study demonstrates that dogs with stage I and papular dermatitis present
lower specific antibody levels and blood parasitemia and higher specific IFN-γ concentrations after
blood stimulation than dogs with more severe disease. Moreover, TLR2 transcript in dogs with mild
disease was similar to that of healthy control dogs. On the other hand, TLR2 transcript in the blood of
dogs with at least stage II was significantly higher than in healthy control dogs. The results from this
study show distinctive immune responses in dogs with CanL. Moreover, immunological characteristics
that were observed in dogs with stage I and papular dermatitis, together with low bood parasitemia,
are indicative of the control of Leishmania infection.
Supplementary Materials: The following are available online at http://www.mdpi.com/2306-7381/5/1/31/s1,
Table S1: Two-fold serial dilution ELISA classification in sera sample, Table S2: Parasite load classification in
whole blood.
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